Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Kraemer, Susanne ^a   Minarzyk, Anette ^a   Forst, Thomas ^b   Kopf, Daniel ^c   Hundemer, Hans Peter ^a  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b Institute for Clinical Research IKFE   (Germany)

^c Frauenklinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; C REACTIVE PROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COMORBIDITY; CONFIDENCE INTERVAL; FEMALE; GERMANY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PREVALENCE; RISK FACTOR; SCHIZOPHRENIA; TREATMENT OUTCOME; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; C-REACTIVE PROTEIN; FEMALE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA;

EID: 80055040253     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-173     Document Type: Article

References (38)

1. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998, 173:11-53. 10.1192/bjp.173.1.11, 9850203.
2. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3:A42. 1563985, 16539783.
3. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study. (FIN11 study). Lancet 2009, 374(9690):620-627. 10.1016/S0140-6736(09)60742-X, 19595447.
4. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008, 337:a1227. 10.1136/bmj.a1227, 2526549, 18755769.
5. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000, 177:212-217. 10.1192/bjp.177.3.212, 11040880.
6. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007, 68(Suppl 4):8-13.
7. Ray WA, Chung C, Murray KT, Hall K, Stein M. Atypical antipsychitoc drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225-235. 10.1056/NEJMoa0806994, 2713724, 19144938.
8. Langfeldt G. The insulin tolerance test in mental disorders. Acta Psychiatr Neurol Scand Suppl 1952, 80:189-199.
9. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 2004, 47:S64-S66.
10. Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. J Clin Exp Psychopathol 1959, 20(1):53-57.
11. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002, 26:137-141. 10.1038/sj.ijo.0801840, 11791159.
12. Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 2003, 29(2):393-397.
13. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010, 119(1-3):101-109. 10.1016/j.schres.2010.02.1030, 20219322.
14. Vancampfort D, Knapen J, Probst M, van Winkel R, Deckx S, Maurissen K, Peuskens J, De Hert M. Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res 2010, 177(3):271-279. 10.1016/j.psychres.2010.03.011, 20406713.
15. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003, 23:328-335. 10.1097/01.jcp.0000085404.08426.3a, 12920407.
16. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psych 2004, 65(Suppl 18):27-35.
17. van Winkel R, Moons T, Peerbooms O, Rutten B, Peuskens J, Claes S, van Os J, De Hert M. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. Int Clin Psychopharmacol 2010, 25(5):270-276. 10.1097/YIC.0b013e32833bc60d, 20523222.
18. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765.
19. Expert Panel on Detection, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National. Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702, Expert Panel on Detection, and Treatment of High Blood Cholesterol in Adults.
20. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366(9491):1059-1062. 10.1016/S0140-6736(05)67402-8, 16182882.
21. , . Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, (ed) S3-Leitlinie Schizophrenie. 2006, Darmstadt, Germany, Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, (ed).
22. . NICE (National Collaborating Centre for Mental Health, National Institute of Clinical Excellence) Schizophrenia: Core interventions in the treatment and management of Schizophrenia in primary and secondary care. Clinical Practice Guideline 82. NICE 2009, (accessed 26 Jan 2010), NICE (National Collaborating Centre for Mental Health, National Institute of Clinical Excellence)., http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf
23. Consensus Statement Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004, 27(2):596-601. Consensus Statement.
24. Pfützner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006, 8:28-36. 10.1089/dia.2006.8.28, 16472048.
25. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160:284-289. 10.1176/appi.ajp.160.2.284, 12562574.
26. Larsen ML, Høder M. Metabolic evaluation of non-insulin-dependent diabetes in primary health care - the clinical usefulness of glycated haemoglobin measurements. Scand J Prim Health Care 1989, 7(3):167-71. 10.3109/02813438909087235, 2587872.
27. Guy W, . (ed) ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338 1976, 218-222. Washington, DC: US Department of Health, Education and Welfare, (ed).
28. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80(1):19-32. 10.1016/j.schres.2005.07.014, 16137860.
29. Gesundheitsberichterstattung des Bundes Indikator 3.19 des Indikatorensatzes der GBE der Länder: Häufigste Diagnosen in Praxen von Allgemeinmedizinerinnen und -medizinern und praktischen Ärztinnen und Ärzten (in % der Behandlungsfälle) nach Geschlecht, Rang und Anteil, Nordrhein, ab. 2002, Gesundheitsberichterstattung des Bundes., http://www.gbe-bund.de/gbe10/abrechnung. prc_abr_test_logon?p_uid=gast&p_aid = 4711&p_sprache=D&p_knoten=TR200
30. Moebus S, Hanisch JU, Neuhäuser M, Aidelsburger P, Wasem J, Jöckel KH. Assessing the prevalence of the Metabolic Syndrome according to NCEP ATP III in Germany: feasibility and quality aspects of a two step approach in 1550 randomly selected primary health care practices. Ger Med Sci 2006, 9:4.
31. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
32. Torres JL, Ridker PM. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol 2003, 18(6):471-478. 10.1097/00001573-200311000-00008, 14597888.
33. Perkins KA, Epstein LH, Stiller RL, Fernstrom MH, Sexton JE, Jacob RG, Solberg R. Acute effects of nicotine on hunger and caloric intake in smokers and nonsmokers. Psychopharmacology (Berl) 1991, 103(1):103-109.
34. Gesundheitsberichterstattung des Bundes Krankheiten/Gesundheits-probleme. Gesundheitsberichterstattung des Bundes., http://www.gbe-bund.de/gbe10/abrechnung. prc_abr_test_logon?p_uid=gast&p_aid = 5813485&p_sprache=D&p_knoten=TR8500
35. Evangelista O, Mc Laughlin MA. Review of cardiovascular risk factors in women. Gend Med 2009, 6(Suppl 1):17-36.
36. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wambers M, Scheen A, Peuskens J. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2006, 2:14.
37. Larsen J, Holdrup M, Christensen B, Sigalin C, Nilsson PM, Kolb S. Interventions in antipsychotics-treated patients with cardiometabolic risk factors or metabolic syndrome. Eur Neuropsychopharmacol 2008, 18(Suppl 4):440-441.
38. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007, 90(1-3):162-173. 10.1016/j.schres.2006.09.025, 17123783.